1. Introduction

Stem cell therapy is an important area of modern biotechnology and regenerative medicine. It involves the use of stem cells to repair, replace, regenerate or restore damaged tissues, organs and biological functions.

Stem cells have the capacity to:

Self-renew by producing more stem cells.

Differentiate into specialized cells.

Repair or replace damaged tissues.

Potentially treat certain blood disorders, immune disorders and degenerative conditions.

However, stem cell therapy raises significant legal and ethical concerns involving patient safety, informed consent, clinical-trial authorization, scientific evidence, commercialization, intellectual property, genetic privacy and medical negligence.

Stem cell therapy regulation refers to the legal framework governing the collection, processing, storage, research, clinical testing, manufacturing, marketing and therapeutic administration of stem cells.

The central regulatory objective is to ensure that scientific innovation does not compromise patient safety, human dignity and fundamental rights.

2. Types of Stem Cells and Their Legal Significance

How mRNA Could Cure Sickle Cell Gene Mutations - William A. Haseltine PhD William A. Haseltine PhD

1. Adult stem cells

Obtained from adult tissues, bone marrow and blood. Hematopoietic stem-cell transplantation is an established treatment for certain blood cancers and blood disorders.

Human embryonic stem cell colony | Nikon Small World

2. Embryonic stem cells

Derived from early-stage embryos. Their use raises questions concerning embryo protection, reproductive ethics and consent.

What are Stem Cells? — About Stem Cells

3. Induced pluripotent stem cells (iPSCs)

Adult cells reprogrammed to acquire pluripotent characteristics. Their regulation involves genetic manipulation, laboratory standards and long-term safety.

Human Bone Marrow Mesenchymal Stem Cells - Innoprot Cell Systems

4. Mesenchymal stem cells

Commonly investigated for tissue repair and immunomodulatory applications. Their therapeutic use requires evidence of safety and efficacy for the particular indication.

3. Legal Framework Governing Stem Cell Therapy in India

India regulates stem-cell research and therapy through a combination of legislation, regulatory guidelines and institutional oversight.

A. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act provides the principal statutory framework for regulating drugs and certain biological products.

Stem-cell products intended for therapeutic use are subject to applicable drug-regulatory requirements.

Important regulatory issues include:

Approval of investigational products.

Manufacturing and quality-control standards.

Licensing and regulatory inspection.

Clinical-trial authorization.

Safety, efficacy and adverse-event monitoring.

Regulation of unauthorized therapeutic claims.

The classification and regulatory pathway depend on the nature and intended use of the cell-based product.

B. New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019 establish requirements concerning clinical trials and new drugs.

Relevant requirements include:

Regulatory permission where required.

Approval from an appropriately constituted Ethics Committee.

Informed consent of participants.

Compliance with clinical-trial protocols.

Reporting of serious adverse events.

Compensation where legally applicable.

Maintenance of clinical-trial records.

The Central Drugs Standard Control Organisation (CDSCO) plays an important regulatory role.

C. ICMR–DBT National Guidelines for Stem Cell Research

The Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT) issued the National Guidelines for Stem Cell Research, 2017.

These guidelines provide standards for:

Basic stem-cell research.

Procurement and donation of biological materials.

Embryonic stem-cell research.

Stem-cell banking.

Preclinical research.

Clinical research.

Institutional oversight.

Ethical approval.

Responsible commercialization.

The guidelines distinguish between established therapeutic applications and experimental interventions.

Important principle: A stem-cell procedure cannot be considered an established treatment merely because it is scientifically promising or commercially advertised.

D. Institutional Committee for Stem Cell Research (IC-SCR)

Institutions undertaking stem-cell research are expected to establish appropriate oversight mechanisms.

The IC-SCR examines scientific and ethical aspects of research, monitors compliance and coordinates with the relevant national regulatory bodies where necessary.

E. Human Embryo and Reproductive Regulation

Embryonic stem-cell research raises additional legal questions involving embryo creation, use, donation and destruction.

Relevant legislation includes:

Assisted Reproductive Technology (Regulation) Act, 2021.

Surrogacy (Regulation) Act, 2021.

Applicable ICMR–DBT ethical guidelines.

These laws and guidelines must be considered according to the particular research activity.

F. Drugs and Cosmetics Rules, 1945

These Rules supplement the statutory framework by regulating the manufacture, quality, testing, import and distribution of drugs.

Where stem-cell products fall within the applicable drug-regulatory classification, manufacturers must comply with the relevant licensing, quality-control and inspection requirements.

G. Clinical Establishments (Registration and Regulation) Act, 2010

This legislation regulates clinical establishments in states and union territories that have adopted it.

It is relevant to:

Registration of hospitals and clinics.

Minimum standards of healthcare facilities.

Regulatory inspection.

Cancellation of registration.

Penalties for statutory non-compliance.

The Supreme Court's 2026 judgment discussed Sections 32 and 40 in relation to enforcement against unauthorized stem-cell treatment.

4. Regulatory Authorities and Their Responsibilities

An important institutional development occurred in March 2024, when the National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT) was dissolved. The subsequent Supreme Court judgment addressed the regulatory uncertainty created by that decision.

5. Clinical Trial Approval and Regulatory Procedure

Stem-cell treatment cannot automatically become lawful simply because a hospital has obtained ordinary medical registration.

The regulatory pathway depends on the nature of the cells, the degree of manipulation and the proposed therapeutic application.

General regulatory pathway

Stem-cell research proposal

Scientific and ethical review

IC-SCR and Ethics Committee, as applicable

Regulatory authorization

CDSCO approval where required under the applicable pathway

Approved clinical trial

Protocol compliance, informed consent and safety monitoring

Evidence assessment and regulatory review

Approved therapeutic use, where authorized

The major regulatory requirements include:

1. Preclinical evaluation: Laboratory and animal studies to assess toxicity, tumour formation, immune reactions and biological stability.

2. Ethical approval: Independent review of research proposals and participant-protection measures.

3. Informed consent: Patients must understand the experimental nature of treatment, possible risks, alternatives and expected benefits.

4. Clinical-trial registration: Applicable trials must satisfy registration requirements, including registration with the Clinical Trials Registry–India (CTRI).

5. Manufacturing standards: Cell processing must comply with applicable Good Manufacturing Practice (GMP) and quality requirements.

6. Safety monitoring: Adverse events and long-term complications must be recorded and reported.

7. Compensation: Applicable clinical-trial injury and compensation provisions must be followed.

6. Important Case Laws on Stem Cell Therapy Regulation

The following decisions are particularly significant for understanding the Indian regulatory position.

Case 1. Yash Charitable Trust v. Union of India (2026)

Landmark Supreme Court judgment

Citation: 2026 INSC 96, W.P. (C) No. 369 of 2022, decided on 30 January 2026.

Court: Supreme Court of India.

Facts:

The petition concerned the promotion and administration of stem-cell therapy for Autism Spectrum Disorder (ASD).

Clinics were allegedly offering experimental stem-cell interventions as routine medical treatment, despite insufficient scientific evidence supporting their effectiveness.

The petitioners argued that such practices violated the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019 and the National Guidelines for Stem Cell Research, 2017.

Legal issues:

Whether stem-cell therapy for ASD could be offered as routine medical treatment.

Whether patient consent could legalize an unproven treatment.

Whether stem-cell research required clinical-trial authorization.

Whether the 2017 guidelines had enforceable legal significance.

Judgment:

The Supreme Court held that stem-cell therapy for ASD cannot be offered as a routine clinical service outside an approved and monitored clinical-trial or research setting.

The Court clarified that:

Stem-cell-derived products involving substantial or more than minimal manipulation are subject to the new-drug regulatory framework.

Stem cells not substantially manipulated may fall outside the definition of a new drug under the NDCT Rules, but their research use remains subject to the applicable biomedical research framework.

Rules 15 and 16(4) of the NDCT Rules give binding effect to the National Ethical Guidelines.

Stem-cell research involving human participants must be conducted within a clinical-trial setting, except for the recognized exception of hematopoietic stem-cell transplantation for haematological disorders.

The Court also held that removing the Department of Health Research's regulatory role through the 2024 executive order was ineffective to the extent that it conflicted with statutory Rules 17 and 18.

Legal significance:

This decision is particularly important because it establishes that experimental stem-cell interventions cannot be commercialized as ordinary medical services merely by obtaining patient consent.

It also connects stem-cell regulation with professional misconduct, clinical-establishment registration and statutory enforcement.

Sci API+1

Case 2. Dalip Kaur and Another v. Union of India and Another (2023)

Citation: W.P.(C) No. 6850 of 2023, Delhi High Court, interim order dated 31 August 2023.

Facts:

The petition challenged recommendations of the Ethics and Medical Registration Board of the National Medical Commission concerning stem-cell treatment for ASD.

The petitioners were concerned about the consequences of discontinuing ongoing treatment.

Legal issue:

Whether patients already undergoing stem-cell interventions could continue them in light of the professional-conduct recommendations.

Decision:

The Delhi High Court granted interim permission for continuation of treatment in the circumstances before it, emphasizing patient autonomy, informed choice and the potential consequences of abrupt discontinuation.

The Court's order was an interim, fact-specific direction, not a general authorization for commercial stem-cell treatment.

Legal significance:

The case illustrates the relationship between patient autonomy and regulatory restrictions.

Importantly, the Supreme Court subsequently considered this dispute in Yash Charitable Trust and clarified that consent cannot create a right to demand scientifically unvalidated treatment outside the legally prescribed framework.

Sci API+1

Case 3. Samira Kohli v. Dr. Prabha Manchanda (2008)

Citation: (2008) 2 SCC 1.

Court: Supreme Court of India.

Facts:

The case concerned the requirement of informed consent before medical procedures.

The patient had consented to a diagnostic procedure, but the doctor performed additional operative procedures without obtaining appropriate consent.

Legal issue:

Whether consent for one medical procedure authorizes a doctor to undertake additional procedures.

Judgment:

The Supreme Court emphasized that valid medical consent must be voluntary and based on adequate information about the nature and purpose of the procedure, its benefits, risks and available alternatives.

Application to stem-cell therapy:

Before administering experimental stem cells, doctors should explain:

Whether the treatment is approved or experimental.

The available scientific evidence.

Potential complications.

The possibility of treatment failure.

Alternative treatments.

Financial costs and clinical-trial protections.

Consent cannot be obtained through exaggerated claims of guaranteed recovery.

Legal significance: The judgment establishes an important foundation for patient autonomy and informed consent in regenerative medicine.

Case 4. Jacob Mathew v. State of Punjab (2005)

Citation: (2005) 6 SCC 1.

Court: Supreme Court of India.

Facts:

The case involved allegations of medical negligence resulting in a patient's death.

Legal issue:

The Court considered the standards for establishing criminal medical negligence.

Judgment:

The Supreme Court explained the distinction between an ordinary medical error and gross negligence sufficient to attract criminal liability.

Application to stem-cell therapy:

A practitioner administering stem-cell treatment may face legal consequences where the conduct amounts to negligence, such as:

Failure to assess medical suitability.

Improper cell processing.

Failure to monitor complications.

Misrepresentation of treatment effectiveness.

Administration contrary to established medical and regulatory standards.

The precise liability depends on the evidence and applicable legal requirements.

Legal significance: The decision provides a general framework for assessing medical negligence in emerging medical technologies.

Case 5. State of Madhya Pradesh v. G.S. Dall and Flour Mills (1992)

Citation: 1992 Supp (1) SCC 150.

Court: Supreme Court of India.

Legal principle:

Executive instructions may supplement statutory provisions where the law is silent, but cannot override or contradict statutory rules.

Application to stem-cell regulation:

In Yash Charitable Trust, the Supreme Court relied on this principle to explain why an executive order cannot remove statutory regulatory safeguards under the NDCT Rules.

The judgment protects the supremacy of statutory regulation over inconsistent administrative instructions.

Case 6. Jaiveer Singh v. State of Uttarakhand (2024)

Citation: (2024) 15 SCC 227.

Court: Supreme Court of India.

Legal principle:

Government authorities cannot amend or supersede statutory rules through administrative instructions.

Application:

The principle is relevant to stem-cell research because regulatory authorities must act within the powers granted by legislation and statutory rules.

Sci API+1

7. International Case Laws and Comparative Regulatory Approaches

International decisions provide useful comparative guidance for India.

A. United States v. US Stem Cell Clinic, LLC (2019)

Court: United States District Court for the Southern District of Florida.

Facts:

The US Food and Drug Administration (FDA) initiated proceedings against a clinic marketing adipose-tissue-derived stem-cell products.

The dispute concerned whether the products were being manufactured and administered in violation of federal drug and biological-product requirements.

Decision:

The federal court granted summary judgment against the clinic and found that the products were adulterated and misbranded under applicable federal law.

A subsequent permanent injunction prohibited the relevant manufacturing and distribution activities until legal compliance was achieved.

Legal significance:

The decision demonstrates that stem-cell treatments marketed as personalized or naturally derived are not automatically exempt from drug-regulatory requirements.

FDA+1

B. United States v. Regenerative Sciences, LLC (2012)

Citation: 741 F.3d 1314 (D.C. Cir. 2014).

Court: United States Court of Appeals for the District of Columbia Circuit.

Facts:

The dispute involved a clinic using cultured and manipulated autologous stem cells for treatment.

The clinic argued that its procedures were medical practice rather than manufacturing regulated biological products.

Decision:

The appellate court upheld the application of federal drug regulation to the relevant cultured cell products.

Legal significance:

The case illustrates the importance of distinguishing minimally manipulated cells from products that undergo substantial processing.

It is useful for comparative analysis of India's regulatory treatment of cell-based products.

8. Patient Rights and Stem Cell Therapy

Stem-cell regulation is closely connected with constitutional and consumer rights.

A. Right to Health

Article 21 of the Constitution of India protects life and personal liberty. Judicial interpretation has recognized the importance of healthcare and medical treatment within this protection.

Patients must receive healthcare consistent with applicable medical and legal standards.

B. Right to Informed Consent

Patients have the right to receive accurate information before participating in experimental research.

Doctors must not conceal the experimental nature of a procedure.

C. Right to Privacy

Stem-cell research may involve genetic information, biological samples and personal medical records.

The handling of such information must comply with applicable privacy and data-protection laws.

D. Right Against Medical Exploitation

Patients suffering from serious or incurable conditions may be particularly vulnerable to exaggerated therapeutic claims.

Regulation must prevent:

False promises of recovery.

Unauthorized clinical interventions.

Misleading advertisements.

Unethical collection of biological materials.

Commercial exploitation of vulnerable patients.

E. Consumer Protection

Where medical services involve deficiencies, misleading representations or unfair trade practices, the Consumer Protection Act, 2019 may become relevant, subject to applicable principles governing medical services and consumer jurisdiction.

9. Ethical Issues in Stem Cell Therapy

10. Liability for Illegal or Unsafe Stem Cell Therapy

Different forms of legal liability may arise depending on the circumstances.

1. Civil liability: A patient may seek compensation for negligence, breach of duty or other legally actionable harm.

2. Criminal liability: Criminal proceedings may arise where the facts satisfy the applicable criminal-law requirements.

3. Professional disciplinary liability: Doctors may face proceedings for professional misconduct under applicable medical regulations.

4. Regulatory liability: Unauthorized manufacturing, clinical trials or distribution may attract action under the Drugs and Cosmetics Act and NDCT Rules.

5. Institutional liability: Hospitals and clinics may face regulatory action, including cancellation of registration where statutory conditions are met.

6. Consumer liability: Misleading advertising or deficient medical services may attract consumer-law remedies.

11. Important Regulatory Developments in India During 2026

Important recent development

Two developments are particularly important.

A. Supreme Court judgment of 30 January 2026

In Yash Charitable Trust v. Union of India, the Supreme Court clarified the legal framework governing stem-cell products and therapeutic interventions.

It also directed attention to the need for stronger national regulatory oversight.

The Court held that non-compliance with the statutory framework could attract:

Professional misconduct proceedings under Regulation 7.22 of the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002.

Cancellation of clinical-establishment registration.

Penalties under Sections 32 and 40 of the Clinical Establishments Act, where applicable.

B. Ministry of Health advisory of 16 September 2026

The Ministry of Health and Family Welfare issued an advisory to states and union territories concerning the regulation of stem-cell therapy.

The advisory reiterates that stem-cell therapy may be offered as standard clinical care only for disease conditions and indications included in the Ministry-approved list.

It specifically states that stem-cell treatment for Autism Spectrum Disorder must remain restricted to duly approved clinical trials.

The National Medical Commission also reiterated that unauthorized administration, prescription, promotion or advertisement beyond approved indications may constitute professional misconduct.

Press Information Bureau+1

12. Major Challenges in Stem Cell Therapy Regulation

Despite developments in the legal framework, several challenges remain.

1. Scientific uncertainty: Long-term safety and effectiveness have not been established for many proposed applications.

2. Regulatory ambiguity: Different regulatory pathways apply to minimally manipulated cells and substantially manipulated cell-derived products.

3. Cross-border treatment: Patients may travel to other countries for unapproved procedures, creating questions about jurisdiction and accountability.

4. Commercial exploitation: Private clinics may advertise experimental procedures as guaranteed cures.

5. Insufficient monitoring: Long-term follow-up is necessary to identify delayed complications.

6. Intellectual property conflicts: Patents, licensing and ownership of stem-cell technologies can create disputes between researchers, institutions and commercial manufacturers.

7. Enforcement difficulties: Effective coordination between CDSCO, ICMR, NMC, state authorities and clinical establishments is essential.

13. Suggestions for Improving Stem Cell Therapy Regulation

India could strengthen the regulatory framework through the following measures:

Establish a dedicated national stem-cell regulatory authority.

Maintain a publicly accessible register of approved stem-cell clinical trials.

Establish clear distinctions between research, experimental treatment and standard medical care.

Introduce strict penalties for false therapeutic advertisements.

Strengthen independent ethical review.

Improve long-term patient monitoring.

Establish uniform standards for stem-cell laboratories and banks.

Improve international cooperation on cross-border stem-cell treatment.

Strengthen compensation mechanisms for research-related injuries.

Promote transparent disclosure of clinical evidence and treatment outcomes.

14. Conclusion

Stem-cell therapy regulation represents an important intersection of biotechnology law, medical ethics, constitutional rights, pharmaceutical regulation and patient protection.

India has developed a regulatory framework through the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, the National Guidelines for Stem Cell Research, 2017 and related institutional regulations.

The Supreme Court's decision in Yash Charitable Trust v. Union of India (2026 INSC 96) is a particularly significant development. It clarifies that stem-cell research involving human participants must comply with the applicable clinical-trial and ethical safeguards, subject to the recognized hematopoietic stem-cell transplantation exception.

The September 2026 Ministry advisory further reinforces restrictions on unapproved therapeutic applications.

Ultimately, the law must maintain a balance between scientific innovation, patient autonomy, medical accountability and public safety. Stem-cell research should be encouraged, but experimental procedures must not be misrepresented as established medical treatments.

15. Important Legal References for Academic Study

Primary reading materials:

ICMR–DBT National Guidelines for Stem Cell Research, 2017.

CDSCO – Stem Cells and Cell-Based Products.

Supreme Court judgment – Yash Charitable Trust v. Union of India, 2026.

Ministry of Health advisory, 17 September 2026.

US FDA – US Stem Cell Clinic regulatory case, 2019.

Key legal principle: Scientific possibility does not automatically establish therapeutic legitimacy. A stem-cell intervention must satisfy the applicable standards of scientific evidence, regulatory authorization, ethical approval and patient protection before it can lawfully be offered as standard clinical care.